BR112014012180A2 - composições farmacêuticas compreendendo álcool perilílico, álcool iso-perilílico e seus derivados enriquecidos de deutério - Google Patents
composições farmacêuticas compreendendo álcool perilílico, álcool iso-perilílico e seus derivados enriquecidos de deutérioInfo
- Publication number
- BR112014012180A2 BR112014012180A2 BR112014012180A BR112014012180A BR112014012180A2 BR 112014012180 A2 BR112014012180 A2 BR 112014012180A2 BR 112014012180 A BR112014012180 A BR 112014012180A BR 112014012180 A BR112014012180 A BR 112014012180A BR 112014012180 A2 BR112014012180 A2 BR 112014012180A2
- Authority
- BR
- Brazil
- Prior art keywords
- alcohol
- enriched
- deuterium
- perilyl alcohol
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/05—Alcohols containing rings other than six-membered aromatic rings
- C07C33/14—Alcohols containing rings other than six-membered aromatic rings containing six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Radiology & Medical Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161562105P | 2011-11-21 | 2011-11-21 | |
| US13/566,731 US8916545B2 (en) | 2010-08-27 | 2012-08-03 | Pharmaceutical compositions comprising POH derivatives |
| PCT/US2012/066379 WO2013119304A2 (en) | 2011-11-21 | 2012-11-21 | Pharmaceutical compositions comprising deuterium-enriched perillyl alcohol, iso-perillyl alcohol and derivatives thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014012180A2 true BR112014012180A2 (pt) | 2017-05-30 |
Family
ID=48948152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012180A BR112014012180A2 (pt) | 2011-11-21 | 2012-11-21 | composições farmacêuticas compreendendo álcool perilílico, álcool iso-perilílico e seus derivados enriquecidos de deutério |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2782894A4 (https=) |
| JP (2) | JP2015502352A (https=) |
| KR (1) | KR20150000469A (https=) |
| CN (1) | CN103946202A (https=) |
| BR (1) | BR112014012180A2 (https=) |
| CA (1) | CA2856403A1 (https=) |
| HK (1) | HK1201253A1 (https=) |
| WO (1) | WO2013119304A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3056006T3 (en) * | 2010-12-17 | 2026-02-17 | Univ Southern California | Methods and devices for using isoperillyl alcohol |
| CN104945333B (zh) * | 2014-03-27 | 2018-02-02 | 沈阳药科大学 | 紫苏醇类似物及其制备和应用 |
| CN104945335B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏胺类化合物及其制备和应用 |
| CN104945336B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏酸甲酯含氮衍生物及其制备和应用 |
| CN104945334B (zh) * | 2014-03-27 | 2018-02-16 | 沈阳药科大学 | 紫苏醇衍生物及其制备和应用 |
| CN111936125B (zh) * | 2018-02-08 | 2025-03-04 | 南加州大学 | 穿透血脑屏障的方法 |
| CN116789530B (zh) * | 2023-05-16 | 2025-12-19 | 杭州师范大学 | 一种紫苏醇酚类衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272441A (en) * | 1980-03-13 | 1981-06-09 | Fmc Corporation | Preparation of carbamates |
| ATE556706T1 (de) * | 2001-03-23 | 2012-05-15 | Luitpold Pharm Inc | Fettalkohol-arzneimittel-konjugate |
| US20060104997A1 (en) * | 2001-12-11 | 2006-05-18 | Constantinides Panayiotis P | Monoterpene compositions and uses thereof |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| CN101010077A (zh) * | 2004-06-23 | 2007-08-01 | 罗伯特·F·霍夫曼 | 靶向的氧化性治疗制剂在烧伤治疗中的用途 |
| WO2007053189A2 (en) | 2005-06-01 | 2007-05-10 | Northwestern University | Compositions and methods for altering immune function |
| US20100168228A1 (en) * | 2006-10-13 | 2010-07-01 | Reliance Life Sciences Pvt. Ltd. | Novel chemotherapeutic agents against inflammation and cancer |
| EP2393488B1 (en) * | 2009-02-06 | 2019-06-19 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
| DK3685835T3 (da) * | 2010-08-27 | 2025-07-21 | Univ Southern California | Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol |
| CN101979378B (zh) * | 2010-10-13 | 2012-06-27 | 中国科学院上海有机化学研究所 | 一种手性γ-内酰胺化合物的合成方法 |
-
2012
- 2012-11-21 HK HK15101876.0A patent/HK1201253A1/xx unknown
- 2012-11-21 CN CN201280057166.6A patent/CN103946202A/zh active Pending
- 2012-11-21 WO PCT/US2012/066379 patent/WO2013119304A2/en not_active Ceased
- 2012-11-21 BR BR112014012180A patent/BR112014012180A2/pt not_active IP Right Cessation
- 2012-11-21 KR KR20147016865A patent/KR20150000469A/ko not_active Withdrawn
- 2012-11-21 JP JP2014542593A patent/JP2015502352A/ja active Pending
- 2012-11-21 CA CA2856403A patent/CA2856403A1/en not_active Abandoned
- 2012-11-21 EP EP12867815.8A patent/EP2782894A4/en not_active Withdrawn
-
2017
- 2017-08-24 JP JP2017161091A patent/JP2018035148A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2782894A4 (en) | 2015-03-11 |
| WO2013119304A2 (en) | 2013-08-15 |
| KR20150000469A (ko) | 2015-01-02 |
| WO2013119304A3 (en) | 2013-10-03 |
| CA2856403A1 (en) | 2013-08-15 |
| CN103946202A (zh) | 2014-07-23 |
| JP2018035148A (ja) | 2018-03-08 |
| JP2015502352A (ja) | 2015-01-22 |
| HK1201253A1 (en) | 2015-08-28 |
| EP2782894A2 (en) | 2014-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014012180A2 (pt) | composições farmacêuticas compreendendo álcool perilílico, álcool iso-perilílico e seus derivados enriquecidos de deutério | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| BR112013004698A2 (pt) | composições farmacêuticas compreendendo derivados de poh | |
| CR20140108A (es) | Compuesto de ciclopropanoamina | |
| DOP2010000011A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CU23821A3 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| ECSP109934A (es) | Compuesto - 946 | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
| BR112013027119A8 (pt) | novos conjugados ligante-droga (adcs) e uso dos mesmos | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| AR096203A1 (es) | Dosificaciones y métodos para administrar moléculas de ácido nucleico formuladas en lípidos | |
| MX357780B (es) | Derivados policíclicos, proceso para su preparación y su uso farmacéutico. | |
| MX380273B (es) | Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp. | |
| DOP2019000275A (es) | Nuevos derivados de pirazol bicíclicos | |
| BR112015017525A2 (pt) | peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| CR20110599A (es) | Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos | |
| MX2016014548A (es) | Moleculas de fusion derivadas de la toxina colix para suministro oral de una carga biologicamente activa. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| ECSP20023626A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| EP4656641A3 (en) | Methods and devices for using isoperillyl alcohol | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |